Suven Pharmaceuticals Ltd Share Price
(SUVENPHAR)
₹1151▲3.68%
as on 04:01PM, 28 Mar 2025
🔔 Merger Alert
NCLT approves merger of Suven Pharmaceuticals with Cohance Lifesciences, expected to create a diversified CDMO platform by Q1 FY26.
Suven Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,091Day's Price Range₹1,159.952 Week's Low
52 Week's High
₹59852-Week Price Range₹1,360
| Returns % | |
| 1 Month Return | -8.6 % |
| 3 Month Return | -2.91 % |
| 1 Year Return | + 63.96 % |
| Market Stats | |
| Previous Close | ₹1,110.20 |
| Open | ₹1,093.45 |
| Volume | 3.17L |
| Upper Circuit | ₹1,332.20 |
| Lower Circuit | ₹888.20 |
| Market Cap | ₹28,261.80Cr |
Suven Pharmaceuticals Ltd Fundamentals
P/E Ratio
101.11
PEG Ratio
-28.09
Market Cap
₹28,261.80 Cr
P/B Ratio
8.38
EPS
11.8
Dividend Yield
0Sector
Pharmaceuticals
ROE
14.31
Mutual Fund Holdings of Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd Analyst Rating
based on 2 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 2 analysts offering long term price targets for Suven Pharmaceuticals Ltd. An average target of ₹1467.5
Source: S&P Global Market Intelligence
Suven Pharmaceuticals Ltd Share analysis
Suven Pharmaceuticals Ltd price forecast by 2 analysts
Upside of32.18%
High
₹1500
Target
₹1467.50
Low
₹1435
Suven Pharmaceuticals Ltd target price ₹1467.5, a slight upside of 32.18% compared to current price of ₹1151. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Suven Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2027:308.48%
Forecast
Actual
Including amortisation and stock based compensations
Suven Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2027:132.63%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Merges with Cohance Lifesciences - 28 Mar, 2025
Suven Pharmaceuticals has received NCLT approval for its merger with Cohance Lifesciences, creating a diversified CDMO platform. The merger aims to enhance global capabilities and is expected to generate $1 billion in revenue within five years.ICICI Securities Initiates Buy Rating on Suven Pharmaceuticals - 25 Mar, 2025
ICICI Securities has initiated coverage on Suven Pharmaceuticals with a BUY rating and a target price of INR 1,400. The company is poised for significant growth in the CDMO space, driven by its merger with Cohance and strategic acquisitions. Management aims for USD 1 billion in revenue by FY30, with strong projected growth rates.Suven Pharma Reports Strong Q4 2024 Financials - 04 Mar, 2025
Suven Pharma's consolidated net sales for December 2024 reached Rs 307.15 crore, a 39.73% increase year-on-year. Net profit surged 77.27% to Rs 82.88 crore, while EBITDA rose 67.83% to Rs 133.41 crore. EPS improved to Rs 3.26 from Rs 1.84 in the previous year.Suven Pharmaceuticals Shows Potential for Gains - 03 Mar, 2025
Suven Pharmaceuticals Limited (SUVENPHAR) is identified as a mid-cap pharma stock with potential for a 6% gain. The stock has shown consistent support on a rising trendline, making current levels attractive for investment despite previous resistance near Rs. 1,352.
Insights on Suven Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 5 quarters, 46.75 Cr → 82.88 Cr (in ₹), with an average increase of 12.9% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 10.70% to 10.84% in Dec 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 22.25% to 22.37% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 248.85 Cr → 322.86 Cr (in ₹), with an average increase of 12.1% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 70.5% return, outperforming this stock by 6.5%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 50.10% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 50.5%
NEGATIVE IMPACTPrice Dip
In the last 7 days, SUVENPHAR stock has moved down by -8.3%
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 14.12% to 13.15% in Dec 2024 quarter
Suven Pharmaceuticals Ltd Financials
Suven Pharmaceuticals Ltd Index Inclusions
Suven Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 50.1% | 0.00 | |
| Foreign Institutions | 10.84% | 1.34 | |
| Mutual Funds | 13.15% | ||
| Retail Investors | 22.37% | 0.52 | |
| Others | 3.54% | 24.73 |
Suven Pharmaceuticals Ltd Key Indicators
Suven Pharmaceuticals Ltd Valuation
Suven Pharmaceuticals Ltd in the last 5 years
Lowest (4.48x)
March 30, 2020
Industry (53.19x)
March 27, 2025
Today (101.11x)
March 27, 2025
Highest (139.56x)
November 5, 2024
Suven Pharmaceuticals Ltd Earnings and Dividends
Suven Pharmaceuticals Ltd Earnings Results
Suven Pharmaceuticals Ltd’s net profit jumped 77.28% since last year same period to ₹82.88Cr in the Q3 2024-2025. On a quarterly growth basis, Suven Pharmaceuticals Ltd has generated 0.81% jump in its net profits since last 3-months.
Read More about Earnings ResultsSuven Pharmaceuticals Ltd Dividends September,2022
In the quarter ending June 2022, Suven Pharmaceuticals Ltd has declared dividend of ₹1 - translating a dividend yield of 0.96%.
Read More about Dividends
Suven Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Suven Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
Suven Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹28,261.80 Cr | 212.67% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹14,156.99 Cr | 67.4% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹4,891.51 Cr | 14.16% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹13,998.90 Cr | 41.24% | 0.68 | ₹218 Cr | ₹1,296 Cr | |
| BUY | ₹22,405.65 Cr | 177.61% | 0.55 | ₹258 Cr | ₹1,375 Cr |
About Suven Pharmaceuticals Ltd
Revenue: ₹307.15Cr as on December 2024 (Q4 24)
Net Profit: ₹83.29Cr as on December 2024 (Q4 24)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
| Organisation | Suven Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Suven Pharmaceuticals Ltd
What is Suven Pharmaceuticals Ltd price today?
Suven Pharmaceuticals Ltd share price today stands at ₹1151, Open: ₹1093.45, Previous Close: ₹1110.2, High: ₹1159.9, Low: ₹1091, 52 Week High: ₹1360, 52 Week Low: ₹598.
How to Buy Suven Pharmaceuticals Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Suven Pharmaceuticals Ltd shares
What are today's traded volumes of Suven Pharmaceuticals Ltd?
Today's traded volume of Suven Pharmaceuticals Ltd(SUVENPHAR) is 3.17L.
What is today's market capitalisation of Suven Pharmaceuticals Ltd?
Today's market capitalisation of Suven Pharmaceuticals Ltd(SUVENPHAR) is ₹28261.8Cr.
What is the 52 Week High and Low Range of Suven Pharmaceuticals Ltd?
How much percentage Suven Pharmaceuticals Ltd is down from its 52 Week High?
Suven Pharmaceuticals Ltd (SUVENPHAR) share price is ₹1151. It is down -15.37% from its 52 Week High price of ₹1360
How much percentage Suven Pharmaceuticals Ltd is up from its 52 Week low?
Suven Pharmaceuticals Ltd (SUVENPHAR) share price is ₹1151. It is up 92.47% from its 52 Week Low price of ₹598